CAL
PRCT icon

Capital Analysts LLC’s Procept Biorobotics PRCT Stock Holding History

Capital Analysts LLC’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-66
Closed -$2K – 1498
2025
Q3 		$2K Hold
66
– – ﹤0.01% 1381
2025
Q2 		$4K Hold
66
– – ﹤0.01% 1275
2025
Q1 		$4K Hold
66
– – ﹤0.01% 1263
2024
Q4 		$5K Hold
66
– – ﹤0.01% 1156
2024
Q3 		$5K Buy
+66
New +$4.69K ﹤0.01% 1128

Other funds holding PRCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Capital Analysts LLC's PRCT Position: Q4 2025 in Review

Capital Analysts LLC sold out of Procept Biorobotics (PRCT) in Q4 2025, closing a stake of 66 shares — an estimated $2K sold.

Capital Analysts LLC first reported a position in PRCT in Q3 2024 and held it in 5 quarters. The position peaked at $5K in Q4 2024. 263 funds tracked by Wall St. Rank hold PRCT as of Q4 2025.

  • Capital Analysts LLC reported no remaining Procept Biorobotics position as of Q4 2025 after selling out during the quarter.
  • Capital Analysts LLC sold 66 Procept Biorobotics shares in Q4 2025, an estimated $2K.
  • Capital Analysts LLC first reported a position in Procept Biorobotics in Q3 2024 and held it in 5 quarters.
  • Capital Analysts LLC's Procept Biorobotics position peaked at $5K in Q4 2024.
  • 263 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2025.

Based on Capital Analysts LLC's 13F filing for Q4 2025, filed 11 Feb 2026.